uniQure (NASDAQ:QURE) Upgraded at Barclays

Barclays upgraded shares of uniQure (NASDAQ:QURE) to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Several other equities analysts also recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research report on Wednesday, January 14th. The Goldman Sachs Group reduced their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. William Blair reiterated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Stifel Nicolaus dropped their target price on uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Finally, Wells Fargo & Company reduced their target price on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $58.33.

uniQure Stock Performance

NASDAQ QURE opened at $23.66 on Tuesday. The stock has a market cap of $1.47 billion, a PE ratio of -5.39 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a 50-day moving average of $23.73 and a 200-day moving average of $28.28. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. On average, sell-side analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other news, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the sale, the director directly owned 40,145 shares in the company, valued at approximately $1,094,352.70. This represents a 43.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 38,810 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at $620,119.26. The trade was a 65.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 102,247 shares of company stock valued at $2,839,298 over the last ninety days. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently bought and sold shares of QURE. Jefferies Financial Group Inc. bought a new stake in shares of uniQure during the 2nd quarter worth approximately $29,217,000. JPMorgan Chase & Co. raised its position in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Fred Alger Management LLC bought a new stake in uniQure during the third quarter worth $75,320,000. Sofinnova Investments Inc. lifted its stake in uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after purchasing an additional 1,012,585 shares during the last quarter. Finally, Avoro Capital Advisors LLC boosted its holdings in shares of uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after purchasing an additional 819,444 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.